Omalizumab ttCD20

Omalizumab: where does it fit into current asthma management?
[15055248] Cleve Clin J Med 71(3): 251-61 (2004)

Current and future applications of the anti-IgE antibody omalizumab.
[19707429] Biologics 2(1): 67-73 (2008)

Omalizumab and other new drug therapies occupy a small space in asthma disease management.
[19326961] J Manag Care Pharm 15(3): 289-93 (2009)

Omalizumab has a place in therapy for asthma disease management.
[19326960] J Manag Care Pharm 15(3): 284-8 (2009)

Anti-IgE therapy with omalizumab in asthma and allergic rhinitis.
[16179127] Acta Pharm 55(2): 123-38 (2005)

A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.
[18472983] Ther Clin Risk Manag 3(4): 613-9 (2007)

Omalizumab for the treatment of severe persistent allergic asthma.
[19804687] Health Technol Assess 13 Suppl 2(): 31-9 (2009)

Omalizumab: the evidence for its place in the treatment of allergic asthma.
[20694084] Core Evid 3(1): 55-66 (2008)

Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody.
[15748543] Dermatol Online J 11(1): 2 (2005)

Severe asthma and the omalizumab option.
[18489791] Clin Mol Allergy 6(-): 4 (2008)

Effects of omalizumab on markers of inflammation in patients with allergic asthma.
[19839977] Allergy 64(12): 1728-36 (2009)

Anti-immunoglobulin E (omalizumab) therapy in seasonal allergic rhinitis.
[11704613] Am J Respir Crit Care Med 164(8 Pt 2): S18-21 (2001)

Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders.
[11704611] Am J Respir Crit Care Med 164(8 Pt 2): S6-11 (2001)

Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications.
[16478867] Chest 129(2): 466-74 (2006)

Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.
[11958741] Allergol Immunopathol (Madr) 30(2): 94-9 (2002)

Churg-strauss syndrome in patients treated with omalizumab.
[19411292] Chest 136(2): 507-18 (2009)

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.
[21410369] N Engl J Med 364(11): 1005-15 (2011)

Antibody-based therapeutics to watch in 2011.
[21051951] MAbs 3(1): 76-99 (2011)

Antibodies to watch in 2010.
[20065640] MAbs 2(1): 84-100 (2010)

Monoclonal antibodies and other biologic agents in the treatment of asthma.
[20065638] MAbs 1(3): 237-46 (2009)

The use of omalizumab in asthma.
[18425299] Prim Care Respir J 17(2): 62-72 (2008)

Omalizumab: efficacy in allergic disease.
[15507883] Panminerva Med 46(2): 141-8 (2004)

T cell activity in successful treatment of chronic urticaria with omalizumab.
[21791043] Clin Mol Allergy 9(-): 11 (2011)

Omalizumab in allergic diseases, a recent review.
[22053590] Asian Pac J Allergy Immunol 29(3): 209-19 (2011)

Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations.
[20232578] Asian Pac J Allergy Immunol 27(4): 233-6 (2009)

Loss of asthma control after cessation of omalizumab treatment: real life data.
[24683390] Postepy Dermatol Alergol 31(1):1-5 (2014)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Omalizumab ttCD20.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Omalizumab ttCD20.php on line 92